Characterization and risk association of polymorphisms in Aurora kinases A, B and C with genetic susceptibility to gastric cancer development.
Adult
Aged
Alleles
Aurora Kinase A
/ genetics
Aurora Kinase B
Aurora Kinase C
Aurora Kinases
/ genetics
Case-Control Studies
Chromosomal Instability
Female
Gene Frequency
Genetic Association Studies
Genetic Predisposition to Disease
Genotype
Humans
Linkage Disequilibrium
Male
Middle Aged
Odds Ratio
Polymorphism, Single Nucleotide
Risk Factors
Stomach Neoplasms
/ diagnosis
Cancer susceptibility
Chromosomal instability
Gastric cancer
Mitotic kinases
Single nucleotide polymorphisms
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
14 Sep 2019
14 Sep 2019
Historique:
received:
02
10
2018
accepted:
04
09
2019
entrez:
16
9
2019
pubmed:
16
9
2019
medline:
12
2
2020
Statut:
epublish
Résumé
Single nucleotide polymorphisms (SNPs) in genes encoding mitotic kinases could influence development and progression of gastric cancer (GC). Case-control study of nine SNPs in mitotic genes was conducted using qPCR. The study included 116 GC patients and 203 controls. In silico analysis was performed to evaluate the effects of polymorphisms on transcription factors binding sites. The AURKA rs1047972 genotypes (CT vs. CC: OR, 1.96; 95% CI, 1.05-3.65; p = 0.033; CC + TT vs. CT: OR, 1.94; 95% CI, 1.04-3.60; p = 0.036) and rs911160 (CC vs. GG: OR, 5.56; 95% CI, 1.24-24.81; p = 0.025; GG + CG vs. CC: OR, 5.26; 95% CI, 1.19-23.22; p = 0.028), were associated with increased GC risk, whereas certain rs8173 genotypes (CG vs. CC: OR, 0.60; 95% CI, 0.36-0.99; p = 0.049; GG vs. CC: OR, 0.38; 95% CI, 0.18-0.79; p = 0.010; CC + CG vs. GG: OR, 0.49; 95% CI, 0.25-0.98; p = 0.043) were protective. Association with increased GC risk was demonstrated for AURKB rs2241909 (GG + AG vs. AA: OR, 1.61; 95% CI, 1.01-2.56; p = 0.041) and rs2289590 (AC vs. AA: OR, 2.41; 95% CI, 1.47-3.98; p = 0.001; CC vs. AA: OR, 6.77; 95% CI, 2.24-20.47; p = 0.001; AA+AC vs. CC: OR, 4.23; 95% CI, 1.44-12.40; p = 0.009). Furthermore, AURKC rs11084490 (GG + CG vs. CC: OR, 1.71; 95% CI, 1.04-2.81; p = 0.033) was associated with increased GC risk. A combined analysis of five SNPs, associated with an increased GC risk, detected polymorphism profiles where all the combinations contribute to the higher GC risk, with an OR increased 1.51-fold for the rs1047972(CT)/rs11084490(CG + GG) to 2.29-fold for the rs1047972(CT)/rs911160(CC) combinations. In silico analysis for rs911160 and rs2289590 demonstrated that different transcription factors preferentially bind to polymorphic sites, indicating that AURKA and AURKB could be regulated differently depending on the presence of particular allele. Our results revealed that AURKA (rs1047972 and rs911160), AURKB (rs2241909 and rs2289590) and AURKC (rs11084490) are associated with a higher risk of GC susceptibility. Our findings also showed that the combined effect of these SNPs may influence GC risk, thus indicating the significance of assessing multiple polymorphisms, jointly. The study was conducted on a less numerous but ethnically homogeneous Bosnian population, therefore further investigations in larger and multiethnic groups and the assessment of functional impact of the results are needed to strengthen the findings.
Sections du résumé
BACKGROUND
BACKGROUND
Single nucleotide polymorphisms (SNPs) in genes encoding mitotic kinases could influence development and progression of gastric cancer (GC).
METHODS
METHODS
Case-control study of nine SNPs in mitotic genes was conducted using qPCR. The study included 116 GC patients and 203 controls. In silico analysis was performed to evaluate the effects of polymorphisms on transcription factors binding sites.
RESULTS
RESULTS
The AURKA rs1047972 genotypes (CT vs. CC: OR, 1.96; 95% CI, 1.05-3.65; p = 0.033; CC + TT vs. CT: OR, 1.94; 95% CI, 1.04-3.60; p = 0.036) and rs911160 (CC vs. GG: OR, 5.56; 95% CI, 1.24-24.81; p = 0.025; GG + CG vs. CC: OR, 5.26; 95% CI, 1.19-23.22; p = 0.028), were associated with increased GC risk, whereas certain rs8173 genotypes (CG vs. CC: OR, 0.60; 95% CI, 0.36-0.99; p = 0.049; GG vs. CC: OR, 0.38; 95% CI, 0.18-0.79; p = 0.010; CC + CG vs. GG: OR, 0.49; 95% CI, 0.25-0.98; p = 0.043) were protective. Association with increased GC risk was demonstrated for AURKB rs2241909 (GG + AG vs. AA: OR, 1.61; 95% CI, 1.01-2.56; p = 0.041) and rs2289590 (AC vs. AA: OR, 2.41; 95% CI, 1.47-3.98; p = 0.001; CC vs. AA: OR, 6.77; 95% CI, 2.24-20.47; p = 0.001; AA+AC vs. CC: OR, 4.23; 95% CI, 1.44-12.40; p = 0.009). Furthermore, AURKC rs11084490 (GG + CG vs. CC: OR, 1.71; 95% CI, 1.04-2.81; p = 0.033) was associated with increased GC risk. A combined analysis of five SNPs, associated with an increased GC risk, detected polymorphism profiles where all the combinations contribute to the higher GC risk, with an OR increased 1.51-fold for the rs1047972(CT)/rs11084490(CG + GG) to 2.29-fold for the rs1047972(CT)/rs911160(CC) combinations. In silico analysis for rs911160 and rs2289590 demonstrated that different transcription factors preferentially bind to polymorphic sites, indicating that AURKA and AURKB could be regulated differently depending on the presence of particular allele.
CONCLUSIONS
CONCLUSIONS
Our results revealed that AURKA (rs1047972 and rs911160), AURKB (rs2241909 and rs2289590) and AURKC (rs11084490) are associated with a higher risk of GC susceptibility. Our findings also showed that the combined effect of these SNPs may influence GC risk, thus indicating the significance of assessing multiple polymorphisms, jointly. The study was conducted on a less numerous but ethnically homogeneous Bosnian population, therefore further investigations in larger and multiethnic groups and the assessment of functional impact of the results are needed to strengthen the findings.
Identifiants
pubmed: 31521144
doi: 10.1186/s12885-019-6133-z
pii: 10.1186/s12885-019-6133-z
pmc: PMC6744709
doi:
Substances chimiques
Aurora Kinase A
EC 2.7.11.1
Aurora Kinase B
EC 2.7.11.1
Aurora Kinase C
EC 2.7.11.1
Aurora Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
919Subventions
Organisme : ARRS
ID : P1-0390
Organisme : ARRS
ID : J3-5504
Organisme : Federal Ministry of Education and Science of Bosnia and Herzegovina
ID : 05-39-116-23/14
Références
Gene. 2000 May 16;249(1-2):31-45
pubmed: 10831836
Bioinformatics. 2002 Feb;18(2):333-4
pubmed: 11847087
Gastroenterology. 2003 May;124(5):1193-201
pubmed: 12730860
Nucleic Acids Res. 2003 Jul 1;31(13):3651-3
pubmed: 12824386
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Cell Motil Cytoskeleton. 2004 Dec;59(4):249-63
pubmed: 15499654
Nat Rev Cancer. 2005 Jan;5(1):42-50
pubmed: 15630414
Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):84-90
pubmed: 16002116
Int J Cancer. 2006 Jan 15;118(2):505-8
pubmed: 16049965
Oncogene. 2006 Feb 23;25(8):1125-42
pubmed: 16314846
Cancer Lett. 2006 Oct 28;242(2):273-9
pubmed: 16412566
Int J Cancer. 2006 Jul 15;119(2):275-82
pubmed: 16477625
Oncogene. 2006 Nov 16;25(54):7148-58
pubmed: 16715125
Cancer Lett. 2007 Mar 18;247(2):266-72
pubmed: 16762494
J Cell Biol. 2006 Jun 19;173(6):833-7
pubmed: 16769825
Carcinogenesis. 2007 Feb;28(2):350-5
pubmed: 16926177
Best Pract Res Clin Gastroenterol. 2006;20(4):651-74
pubmed: 16997151
Histol Histopathol. 2007 Feb;22(2):191-7
pubmed: 17149692
Breast Cancer Res Treat. 2007 Dec;106(2):205-13
pubmed: 17268814
Clin Cancer Res. 2008 Mar 15;14(6):1639-48
pubmed: 18347165
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7507-12
pubmed: 19372376
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W600-5
pubmed: 19417063
Cold Spring Harb Protoc. 2009 Oct;2009(10):pdb.ip71
pubmed: 20147036
Nat Rev Drug Discov. 2010 Aug;9(8):643-60
pubmed: 20671765
Nat Rev Cancer. 2010 Dec;10(12):825-41
pubmed: 21102634
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W74-8
pubmed: 21576231
PLoS One. 2011;6(10):e26512
pubmed: 22046298
PLoS One. 2012;7(10):e46784
pubmed: 23082130
Dig Dis Sci. 2013 Apr;58(4):978-88
pubmed: 23086128
PLoS One. 2013;8(3):e58609
pubmed: 23472213
Am J Cancer Res. 2013 Aug 14;3(4):339-46
pubmed: 23977444
Clin Cancer Res. 2014 Jan 1;20(1):76-86
pubmed: 24240108
PLoS One. 2014 Mar 05;9(3):e90328
pubmed: 24598702
Mol Cancer. 2014 Apr 26;13:87
pubmed: 24767679
Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):664-74
pubmed: 25134511
Indian J Clin Biochem. 2015 Apr;30(2):134-9
pubmed: 25883419
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Mol Hum Reprod. 2015 Aug;21(8):633-44
pubmed: 25995441
Mol Cell Biol. 2015 Oct;35(20):3566-78
pubmed: 26240282
J Clin Med Res. 2015 Oct;7(10):742-51
pubmed: 26345296
PLoS One. 2016 Apr 26;11(4):e0154378
pubmed: 27116470
IUBMB Life. 2016 Aug;68(8):634-44
pubmed: 27270838
Nucleic Acids Res. 2017 Jan 4;45(D1):D139-D144
pubmed: 27899579
Environ Mol Mutagen. 2017 Dec;58(9):701-711
pubmed: 28843004
Protein Sci. 2018 Jan;27(1):316-330
pubmed: 29067736
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Nat Rev Mol Cell Biol. 2018 Mar;19(3):158-174
pubmed: 29165424
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell. 1995 Apr 7;81(1):95-105
pubmed: 7720077
Nucleic Acids Res. 1996 Jun 15;24(12):2416-21
pubmed: 8710515